Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial
| Autor: | E. Müller, I. Talstad, L. Johansen, Anders Waage, Stein A. Evensen, F. Wisøff |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Adolescent Naphthacenes Daunorubicin medicine.medical_treatment Pharmacology Acute myelogenous leukaemia Refractory Internal medicine Humans Medicine Aclarubicin INDUCTION TREATMENT Aged Chemotherapy Antibiotics Antineoplastic business.industry Complete remission Hematology General Medicine Middle Aged Leukemia Myeloid Acute Drug Evaluation Female business medicine.drug |
| Zdroj: | European Journal of Haematology. 38:43-47 |
| ISSN: | 1600-0609 0902-4441 |
| DOI: | 10.1111/j.1600-0609.1987.tb00021.x |
| Popis: | SUMMARY Nineteen patients with acute myelogenous leukaemia refractory to regimens including daunorubicin (relapsed or resistant to the induction treatment) received aclarubicin as single-agent chemotherapy in a dose of 40 mg/m2 daily for 5–7 days. Among 17 evaluable patients one achieved complete remission, and two obtained partial remission. Side effects were acceptable. The chosen dose of aclarubicin appeared to be suboptimal. However, several arguments suggest that aclarubicin in combination with other cytotoxic agents should be evaluated as first-line chemotherapy of acute myelogenous leukaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text